Tevimbra in Turkey

Tevimbra - overview

Tevimbra (PD‑1 inhibitor; tislelizumab) is manufactured by BeiGene (US partner Novartis) and indicated for Solid tumors. It is a PD-1 mAb approved by the US FDA in 2024 and may be accessible to patients in Turkey through a Named Patient Program or personal-import pathway.

Access in Turkey

Turkey's TITCK operates a named-patient program; HCPs coordinate with Turkish Pharmacists' Association.

How Reserve Meds coordinates access in Turkey

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Turkey-specific eligibility.
3. Treating physician in Turkey issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Tevimbra from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Turkey.

Typical timeline for Turkey

End-to-end, most requests are completed in 2-6 weeks. Turkey's tier 2 regulatory maturity typically supports moderate processing times.

What patients and physicians in Turkey ask

• Is the pathway legal in Turkey? Yes - it operates under Turkey's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Turkey able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Tevimbra in Turkey

Request Tevimbra